Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ETCompany ParticipantsBen R.

Full transcript - Recursion Pharmaceuticals Inc (RXRX) Q2 2025: Chris Gibson, Co-Founder and CEO, Recursion Pharmaceuticals: Recursion’s q two twenty twenty five earnings call.

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.

From a technology perspective, Recursion continued the rollout of Recursion OS 2.0, a platform upgrade integrating Exscientia’s AI-driven chemistry capabilities and large-scale multimodal ...

J. D. Jobson, Bob Korkie, Statistical Inference in Two-Parameter Portfolio Theory with Multiple Regression Software, The Journal of Financial and Quantitative Analysis, Vol. 18, No. 2 (Jun., 1983), pp ...

The Golden State Warriors reportedly want to hold on to two players amid Jonathan Kuminga trade talks with the Sacramento Kings.